CBL-514
Reduction of subcutaneous abdominal fat
Key Facts
About Caliway Biopharmaceuticals
Caliway Biopharmaceuticals is dedicated to developing innovative small-molecule drugs for aesthetic medicine and inflammatory diseases. Its core technology focuses on inducing adipocyte apoptosis (programmed cell death) without surgery. The company has advanced its lead candidate, CBL-514, into mid-stage clinical trials and achieved a significant market valuation following its public listing, positioning it as a key player in the non-invasive aesthetic therapeutics space.
View full company profileAbout Caliway Biopharmaceuticals
Caliway Biopharmaceuticals is dedicated to developing innovative small-molecule drugs for aesthetic medicine and inflammatory diseases. Its core technology focuses on inducing adipocyte apoptosis (programmed cell death) without surgery. The company has advanced its lead candidate, CBL-514, into mid-stage clinical trials and achieved a significant market valuation following its public listing, positioning it as a key player in the non-invasive aesthetic therapeutics space.
View full company profileAbout Caliway Biopharmaceuticals
Caliway Biopharmaceuticals is dedicated to developing innovative small-molecule drugs for aesthetic medicine and inflammatory diseases. Its core technology focuses on inducing adipocyte apoptosis (programmed cell death) without surgery. The company has advanced its lead candidate, CBL-514, into mid-stage clinical trials and achieved a significant market valuation following its public listing, positioning it as a key player in the non-invasive aesthetic therapeutics space.
View full company profile